• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins.利用海肾荧光素酶抗体融合蛋白对细胞表面抗原-抗体相互作用进行定量分析。
MAbs. 2017 Apr;9(3):506-520. doi: 10.1080/19420862.2016.1274844. Epub 2017 Jan 17.
2
Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity.基于抗体的可溶性和膜结合 TWEAK 模拟激动剂,具有 FcγR 非依赖性活性。
Front Immunol. 2023 Jul 11;14:1194610. doi: 10.3389/fimmu.2023.1194610. eCollection 2023.
3
Basic characterization of antibodies targeting receptors of the tumor necrosis factor receptor superfamily.靶向肿瘤坏死因子受体超家族受体的抗体的基本特征。
Front Immunol. 2023 Mar 27;14:1115667. doi: 10.3389/fimmu.2023.1115667. eCollection 2023.
4
CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.CD40 和 CD95 特异性抗体单链-Baff 融合蛋白显示出对 BaffR、TACI 和 BCMA 的限制激动作用。
MAbs. 2020 Jan-Dec;12(1):1807721. doi: 10.1080/19420862.2020.1807721.
5
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.一种 IgG 的工程化 Fc 变体通过结构干扰消除了所有免疫效应功能。
Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17.
6
Generation and Application of Bioluminescent CD95 Ligand Fusion Proteins.生物发光CD95配体融合蛋白的产生与应用
Methods Mol Biol. 2017;1557:63-77. doi: 10.1007/978-1-4939-6780-3_7.
7
A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo.一种新型针对 Fn14 的 llama 抗体在体内显示出抗转移活性。
MAbs. 2014 Jan-Feb;6(1):297-308. doi: 10.4161/mabs.26709.
8
Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.人源单克隆IgG糖变体的多角度效应功能分析
PLoS One. 2015 Dec 11;10(12):e0143520. doi: 10.1371/journal.pone.0143520. eCollection 2015.
9
Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.与HIV-1 gp120 V3环基部反应的同种型和亚类转换的人单克隆抗体的表达及功能活性
AIDS Res Hum Retroviruses. 2003 Jul;19(7):597-607. doi: 10.1089/088922203322230969.
10
Antigen improves binding of IgGs to FcγRs in SPR analysis.抗原可提高 SPR 分析中 IgG 与 FcγR 的结合。
Anal Biochem. 2022 Mar 1;640:114411. doi: 10.1016/j.ab.2021.114411. Epub 2021 Oct 12.

引用本文的文献

1
A Novel Tetravalent CD95/Fas Fusion Protein With Superior CD95L/FasL Antagonism.一种具有卓越CD95L/FasL拮抗作用的新型四价CD95/Fas融合蛋白。
Proteins. 2025 Feb;93(2):441-451. doi: 10.1002/prot.26741. Epub 2024 Sep 1.
2
Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism.基因工程 IgG1 和纳米抗体寡聚体获得了强烈的固有 CD40 激动作用。
Bioengineered. 2024 Dec;15(1):2302246. doi: 10.1080/21655979.2024.2302246. Epub 2024 Jan 12.
3
Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism.基于抗体的肿瘤坏死因子 (TNF) 受体 2(TNFR2)激动剂的通用设计原则,具有 FcγR 非依赖性激动作用。
Theranostics. 2024 Jan 1;14(2):496-509. doi: 10.7150/thno.84404. eCollection 2024.
4
Basic characterization of antibodies targeting receptors of the tumor necrosis factor receptor superfamily.靶向肿瘤坏死因子受体超家族受体的抗体的基本特征。
Front Immunol. 2023 Mar 27;14:1115667. doi: 10.3389/fimmu.2023.1115667. eCollection 2023.
5
A TNFR2-Specific TNF Fusion Protein With Improved Activity.一种具有改良活性的 TNFR2 特异性 TNF 融合蛋白。
Front Immunol. 2022 Jun 13;13:888274. doi: 10.3389/fimmu.2022.888274. eCollection 2022.
6
CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism.CD40 和 41BB 特异性抗体融合蛋白,具有 PDL1 阻断限制的激动作用。
Theranostics. 2022 Jan 1;12(4):1486-1499. doi: 10.7150/thno.66119. eCollection 2022.
7
Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism.抗Fn14抗体偶联纳米颗粒表现出类似膜TWEAK的激动作用。
Pharmaceutics. 2021 Jul 13;13(7):1072. doi: 10.3390/pharmaceutics13071072.
8
Membrane lymphotoxin-αβ is a novel tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist.膜淋巴毒素-αβ是一种新型肿瘤坏死因子(TNF)受体2(TNFR2)激动剂。
Cell Death Dis. 2021 Apr 6;12(4):360. doi: 10.1038/s41419-021-03633-8.
9
CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.CD40 和 CD95 特异性抗体单链-Baff 融合蛋白显示出对 BaffR、TACI 和 BCMA 的限制激动作用。
MAbs. 2020 Jan-Dec;12(1):1807721. doi: 10.1080/19420862.2020.1807721.
10
TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity.TNFRSF 受体特异性抗体融合蛋白,具有靶向控制的 FcγR 非依赖性激动活性。
Cell Death Dis. 2019 Mar 4;10(3):224. doi: 10.1038/s41419-019-1456-x.

本文引用的文献

1
Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 1: Cysteine Residues and Glycans.用于分子成像的位点特异性标记免疫缀合物——第1部分:半胱氨酸残基与聚糖
Mol Imaging Biol. 2016 Feb;18(1):1-17. doi: 10.1007/s11307-015-0919-4.
2
Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.完整细胞上肿瘤坏死因子受体超家族(TNFRSF)受体的结合研究
J Biol Chem. 2016 Mar 4;291(10):5022-37. doi: 10.1074/jbc.M115.683946. Epub 2015 Dec 31.
3
Soluble TL1A is sufficient for activation of death receptor 3.可溶性TL1A足以激活死亡受体3。
FEBS J. 2016 Jan;283(2):323-36. doi: 10.1111/febs.13576. Epub 2015 Nov 24.
4
Genetic code expansion enabled site-specific dual-color protein labeling: superresolution microscopy and beyond.遗传密码扩展实现了位点特异性双色蛋白质标记:超分辨率显微镜及其他应用。
Curr Opin Chem Biol. 2015 Oct;28:164-73. doi: 10.1016/j.cbpa.2015.07.021. Epub 2015 Aug 22.
5
Principles of antibody-mediated TNF receptor activation.抗体介导的肿瘤坏死因子受体激活原理。
Cell Death Differ. 2015 Nov;22(11):1727-41. doi: 10.1038/cdd.2015.109. Epub 2015 Aug 21.
6
The Structural Role of Antibody N-Glycosylation in Receptor Interactions.抗体N-糖基化在受体相互作用中的结构作用
Structure. 2015 Sep 1;23(9):1573-1583. doi: 10.1016/j.str.2015.06.015. Epub 2015 Jul 23.
7
Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions.Fc 受体相互作用调节细胞毒性和免疫调节治疗性抗体的效应功能。
Cancer Immunol Res. 2015 Jul;3(7):704-13. doi: 10.1158/2326-6066.CIR-15-0120.
8
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities.FcγR 依赖性细胞毒性、激动性和中和抗体活性的机制。
Trends Immunol. 2015 Jun;36(6):325-36. doi: 10.1016/j.it.2015.04.005. Epub 2015 May 13.
9
Site-specific protein labeling with SNAP-tags.使用SNAP标签进行位点特异性蛋白质标记。
Curr Protoc Protein Sci. 2013 Sep 24;73:30.1.1-30.1.16. doi: 10.1002/0471140864.ps3001s73.
10
CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.利用 scFv 靶向 TRAIL 突变体对 CD70 限制的 TRAILR1 或 TRAILR2 的特异性激活。
Cell Death Dis. 2014 Jan 30;5(1):e1035. doi: 10.1038/cddis.2013.555.

利用海肾荧光素酶抗体融合蛋白对细胞表面抗原-抗体相互作用进行定量分析。

Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins.

作者信息

Kums Juliane, Nelke Johannes, Rüth Benedikt, Schäfer Viktoria, Siegmund Daniela, Wajant Harald

机构信息

a Division of Molecular Internal Medicine, Department of Internal Medicine II , University Hospital Würzburg , Würzburg , Germany.

出版信息

MAbs. 2017 Apr;9(3):506-520. doi: 10.1080/19420862.2016.1274844. Epub 2017 Jan 17.

DOI:10.1080/19420862.2016.1274844
PMID:28095113
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5384709/
Abstract

Cell surface antigen-specific antibodies are of substantial diagnostic and therapeutic importance. The binding properties of such antibodies are usually evaluated by cell-free assays, in particular surface plasmon resonance (SPR) analysis, or flow cytometry. SPR analyses allow the detailed quantitative and dynamic evaluation of the binding properties of antibodies, but need purified, typically recombinantly produced antigens. It can, however, be difficult to produce the required antigen. Furthermore, cellular factors influencing the antigen-antibody interaction are not considered by this method. Flow cytometry-based analyses do not have these limitations, but require elaborated calibration controls for absolute quantification of bound molecules. To overcome the limitations of SRP and flow cytometry in the characterization of cell surface antigen-specific antibodies, we developed Fn14-specific antibody 18D1 as an example of an antibody fusion protein format that includes the luciferase of Gaussia princeps (GpL), which enables very simple and highly sensitive cellular binding studies. We found that GpL-tagging of the C-terminus of the antibody light chain does not affect the interaction of 18D1-IgG1 with its antigen and Fc-gamma receptors (FcγRs). In accordance with this, the GpL-18D1-IgG1 antibody fusion protein showed basically the same FcγR-dependent agonistic properties as the parental 18D1 antibody. Similar results were obtained with isotype switch variants of 18D1 and antibodies specific for CD95, LTβR and CD40. In sum, we demonstrate that antibody GpL fusion proteins are easily manageable and versatile tools for the characterization of cell surface antigen-antibody interactions that have the potential to considerably extend the instrumentarium for the evaluation of antibodies.

摘要

细胞表面抗原特异性抗体具有重要的诊断和治疗意义。此类抗体的结合特性通常通过无细胞检测进行评估,特别是表面等离子体共振(SPR)分析或流式细胞术。SPR分析能够对抗体的结合特性进行详细的定量和动态评估,但需要纯化的、通常是重组产生的抗原。然而,生产所需的抗原可能会很困难。此外,该方法未考虑影响抗原 - 抗体相互作用的细胞因子。基于流式细胞术的分析不存在这些局限性,但需要精心设计的校准对照来绝对定量结合的分子。为了克服SPR和流式细胞术在表征细胞表面抗原特异性抗体方面的局限性,我们开发了Fn14特异性抗体18D1作为抗体融合蛋白形式的一个例子,该形式包含高斯海萤(GpL)的荧光素酶,这使得非常简单且高度灵敏的细胞结合研究成为可能。我们发现,抗体轻链C末端的GpL标记不会影响18D1 - IgG1与其抗原和Fc - γ受体(FcγRs)的相互作用。据此,GpL - 18D1 - IgG1抗体融合蛋白表现出与亲本18D1抗体基本相同的FcγR依赖性激动特性。用18D1的同种型转换变体以及针对CD95、LTβR和CD40的特异性抗体也获得了类似结果。总之,我们证明抗体GpL融合蛋白是用于表征细胞表面抗原 - 抗体相互作用的易于操作且通用的工具,有可能极大地扩展评估抗体的手段。